Back to Trades
Total Value
$627.8K
Net $382.1K sold
Filing Date
Jul 9, 2026
1 transaction
Sales
$382.1K
1 transaction
Trade Summary
On Jul 7, 2026, Ruiz Briseno Andres, Insider, sold $627.8K of IDEAYA Biosciences, Inc. (IDYA) across 1 transaction. The filing covers Common Stock and reflects net selling of $382.1K. Reported prices ranged from $12.86 to $40.01. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- IDEAYA Biosciences, Inc.
- Ticker Symbol
- IDYA
- CIK
- 0001676725
Insider Information
- Role
- Insider
- Location
- SOUTH SAN FRANCISCO, CA
Filing Details
- Filing Date
- Jul 9, 2026
- Transaction Date
- Jul 7, 2026
- Accession Number
- 0001610717-26-000336
- Form Type
- 4
- Net Trading Amount
- -$382.1K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 7, 2026 | Common Stock | 9,550 | $12.86 | Exercise | $122.8K |
| Jul 7, 2026 | Common Stock | 9,550 | $40.01 | Sale | $382.1K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 7, 2026 | IDYA derivative | 9,550 | $12.86 | Exercise | $122.8K |
Want live alerts when Ruiz Briseno Andres trades again?
Download Insider Trades to track IDYA, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 19, 2025.
- (F2)This transaction was executed in multiple trades in prices ranging from $40.00 to $40.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- (F3)100% of the shares subject to the option is fully vested and exercisable.